Compare ASIC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | ALVO |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | Luxembourg |
| Employees | 203 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2025 | 2021 |
| Metric | ASIC | ALVO |
|---|---|---|
| Price | $26.39 | $5.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $29.10 | $6.80 |
| AVG Volume (30 Days) | 51.7K | ★ 953.0K |
| Earning Date | 10-21-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $424,339,000.00 | N/A |
| Revenue This Year | $27.91 | $11.96 |
| Revenue Next Year | $25.28 | $17.65 |
| P/E Ratio | $22.21 | ★ $18.20 |
| Revenue Growth | ★ 23.41 | N/A |
| 52 Week Low | $16.35 | $2.94 |
| 52 Week High | $29.00 | $9.05 |
| Indicator | ASIC | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 61.19 |
| Support Level | $18.75 | $3.10 |
| Resistance Level | $27.22 | N/A |
| Average True Range (ATR) | 0.80 | 0.29 |
| MACD | -0.30 | -0.03 |
| Stochastic Oscillator | 11.16 | 66.93 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.